U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H10O5
Molecular Weight 258.2262
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SALSALATE

SMILES

OC(=O)C1=CC=CC=C1OC(=O)C2=CC=CC=C2O

InChI

InChIKey=WVYADZUPLLSGPU-UHFFFAOYSA-N
InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)

HIDE SMILES / InChI

Molecular Formula C14H10O5
Molecular Weight 258.2262
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23817699 | https://www.ncbi.nlm.nih.gov/pubmed/6520777

Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: GO:0001516
Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DISALCID

Approved Use

Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder.
Palliative
DISALCID

Approved Use

Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Variable effects of nonsteroidal antiinflammatory agents on thyroid test results.
2003 Dec
Interaction of rofecoxib and celecoxib with warfarin.
2003 Jul 1
Salicylic acid-induced inactivation of creatine kinase in the presence of lactoperoxidase and H2O2.
2005 Jan 15
Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells.
2005 Jan-Feb
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
2006
Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.
2006 Sep
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle.
2008 Aug
Salsalate improves glycemia and inflammatory parameters in obese young adults.
2008 Feb
Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes.
2008 Jul
Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study.
2008 Mar 12
Role of NFkappaB in age-related vascular endothelial dysfunction in humans.
2009 Aug 10
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.
2009 Mar
Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury.
2009 Oct
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats.
2010 Dec
2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts.
2010 Jul
Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults.
2010 Jul 31
Potential role of salicylates in type 2 diabetes.
2010 Jul-Aug
A systems biology approach identifies inflammatory abnormalities between mouse strains prior to development of metabolic disease.
2010 Nov
Wet oxidation of salicylic acid solutions.
2010 Nov 15
Patents

Sample Use Guides

In Vivo Use Guide
The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:10:16 GMT 2023
Edited
by admin
on Fri Dec 15 15:10:16 GMT 2023
Record UNII
V9MO595C9I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SALSALATE
USAN   INN  
Official Name English
DISALCID
Brand Name English
NSC-49171
Code English
DISALICYCLIC ACID
Common Name English
SASAPYRINE
JAN  
Common Name English
2-[(2-Hydroxybenzoyl)oxy]benzoic acid
Systematic Name English
CARBASALATE CALCIUM IMPURITY D [EP IMPURITY]
Common Name English
salsalate [INN]
Common Name English
SALSALATE [MI]
Common Name English
ACETYLSALICYLIC ACID IMPURITY E [EP IMPURITY]
Common Name English
BENZOIC ACID, 2-HYDROXY-, 2-CARBOXYPHENYL ESTER
Common Name English
SALSALATE [MART.]
Common Name English
SALSALATE [USAN]
Common Name English
SALICYLSALICYLIC ACID
Common Name English
Salsalate [WHO-DD]
Common Name English
DL-LYSINE ACETYLSALICYLATE IMPURITY M [EP IMPURITY]
Common Name English
SALSALATE [USP IMPURITY]
Common Name English
SALSALATE [USP-RS]
Common Name English
SASAPYRINE [JAN]
Common Name English
SALSALATE [VANDF]
Common Name English
SALICYLIC ACID, BIMOLECULAR ESTER
Common Name English
SALSALATE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC N02BA06
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
WHO-VATC QN02BA06
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
LIVERTOX NBK548843
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
Code System Code Type Description
NSC
49171
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
LACTMED
Salsalate
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
SMS_ID
100000086562
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
CHEBI
9014
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
RXCUI
36108
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
209-027-4
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
ChEMBL
CHEMBL154111
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
DRUG BANK
DB01399
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
DRUG CENTRAL
2420
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
EVMPD
SUB10434MIG
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
PUBCHEM
5161
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
MERCK INDEX
m9747
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
SALSALATE
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID1023572
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
INN
3267
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
FDA UNII
V9MO595C9I
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
DAILYMED
V9MO595C9I
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
MESH
C014182
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
CAS
552-94-3
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
RS_ITEM_NUM
1609807
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
NCI_THESAURUS
C62636
Created by admin on Fri Dec 15 15:10:17 GMT 2023 , Edited by admin on Fri Dec 15 15:10:17 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
PARENT -> IMPURITY
PARENT -> IMPURITY
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC